Published in Drug Week, December 31st, 2004
Greenacre, a seasoned pharmaceutical executive, will advance the company's capacity to deliver a complete solution to U.S. and European pharmaceutical firms interested in entering the Chinese marketplace.
Greenacre currently serves as a director of Acusphere, Inc., (ACUS); Cephalon, Inc., (CEPH); Curis, Inc., (CRIS); and Immune Response Corp. (IMNR).
Greenacre began his pharmaceutical career with SmithKline & French Laboratories (now part of GlaxoSmithKline PLC), where he was responsible...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week